Basmaeil Yasser, Subayyil Abdullah Al, Kulayb Haya Bin, Kondkar Altaf A, Alrodayyan Maha, Khatlani Tanvir
Stem Cells and Regenerative Medicine Unit, Blood and Cancer Research (BCR) Department, King Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences (KSAU), Ministry of National Guard Health Affairs (MNGHA), Riyadh 11426, Saudi Arabia.
Department of Ophthalmology, College of Medicine, King Saud University, Riyadh 11411, Saudi Arabia.
Cells. 2024 Dec 23;13(24):2131. doi: 10.3390/cells13242131.
Stem cell-based therapies hold significant potential for cancer treatment due to their unique properties, including migration toward tumor niche, secretion of bioactive molecules, and immunosuppression. Mesenchymal stem cells (MSCs) from adult tissues can inhibit tumor progression, angiogenesis, and apoptosis of cancer cells. We have previously reported the isolation and characterization of placenta-derived decidua basalis mesenchymal stem cells (DBMSCs), which demonstrated higher levels of pro-migratory and anti-apoptotic genes, indicating potential anti-cancer effects. In this study, we analyzed the anti-cancer effects of DBMSCs on human breast cancer cell lines MDA231 and MCF7, with MCF 10A used as control. We also investigated how these cancer cells lines affect the functional competence of DBMSCs. By co-culturing DBMSCs with cancer cells, we analyzed changes in functions of both cell types, as well as alterations in their genomic and proteomic profile. Our results showed that treatment with DBMSCs significantly reduced the functionality of MDA231 and MCF7 cells, while MCF 10A cells remained unaffected. DBMSC treatment decreased epithelial-to-mesenchymal transition (EMT)-related protein levels in MDA231 cells and modulated expression of other cancer-related genes in MDA231 and MCF7 cells. Although cancer cells reduced DBMSC proliferation, they increased their expression of anti-apoptotic genes. These findings suggest that DBMSCs can inhibit EMT-related proteins and reduce the invasive characteristics of MDA231 and MCF7 breast cancer cells, highlighting their potential as candidates for cell-based cancer therapies.
基于干细胞的疗法因其独特特性在癌症治疗中具有巨大潜力，这些特性包括向肿瘤微环境迁移、分泌生物活性分子以及免疫抑制。来自成人组织的间充质干细胞（MSCs）可抑制肿瘤进展、血管生成以及癌细胞凋亡。我们之前报道了胎盘来源的基蜕膜间充质干细胞（DBMSCs）的分离与鉴定，其显示出更高水平的促迁移和抗凋亡基因，表明具有潜在的抗癌作用。在本研究中，我们分析了DBMSCs对人乳腺癌细胞系MDA231和MCF7的抗癌作用，以MCF 10A作为对照。我们还研究了这些癌细胞系如何影响DBMSCs的功能能力。通过将DBMSCs与癌细胞共培养，我们分析了两种细胞类型功能的变化以及它们基因组和蛋白质组图谱的改变。我们的结果表明，用DBMSCs处理显著降低了MDA231和MCF7细胞的功能，而MCF 10A细胞未受影响。DBMSC处理降低了MDA231细胞中上皮-间质转化（EMT）相关蛋白水平，并调节了MDA231和MCF7细胞中其他癌症相关基因的表达。尽管癌细胞降低了DBMSC的增殖，但它们增加了抗凋亡基因的表达。这些发现表明，DBMSCs可抑制EMT相关蛋白并降低MDA231和MCF7乳腺癌细胞的侵袭特性，突出了它们作为基于细胞的癌症治疗候选者的潜力。
